CEO Alex Gorsky elected chairman of Johnson & Johnson

Bill Weldon to step down after 41-year career at the company

Johnson & Johnson has elected Alex Gorsky as chairman. He takes over the role on 28 December when current chairman, Bill Weldon, steps down. Weldon plans to retire in the first quarter of 2013, after a brief transitional period.

Gorsky was appointed CEO of Johnson & Johnson in April.

‘I am truly honoured to succeed Bill Weldon as chairman of Johnson & Johnson,’ he said. ‘Bill's leadership and contributions to Johnson & Johnson over a 41-year career leave us well-positioned to continue addressing the world's most prevalent diseases and unmet needs in healthcare.’

You may also like

Finance

Johnson & Johnson completes V-Wave acquisition to support patients with heart failure

The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease
Finance

Johnson & Johnson to acquire heart failure specialist, V-Wave, for up to $1.1bn

The strategic acquisition will boost J&J's offering in the heart disease category
Research & Development

F-star Therapeutics announces license agreement with Janssen

The agreement grants Janssen an exclusive license to research, develop, and commercialise bispecific antibodies directed to its therapeutic targets using F-star’s proprietary Fcab and mAb2 platforms
Research & Development

BioMed X begins research project for oral therapeutics delivery

The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation
Finance

Vifor Pharma enters commercial diabetes collaboration in the US

The Swiss pharma company will work with US-based Janssen to jointly commercialise INVOKANA (canagliflozin) in the US to address complications of type 2 diabetes
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Subscribe now